scholarly journals Változások a pajzsmirigybetegségek radiojódkezelésében

2016 ◽  
Vol 157 (3) ◽  
pp. 83-88
Author(s):  
András Konrády
Keyword(s):  
Multinodular Goiter ◽  
Radioiodine Therapy ◽  
Treatment Protocol ◽  
Treatment Results ◽  
Radioiodine Uptake ◽  
Risk Patients ◽  
Toxic Multinodular Goiter ◽  
Prospective Trials ◽  
Immunogenic Hyperthyroidism ◽  
Recombinant Human Thyrotropin

Radioiodine therapy for benign and malignant thyroid diseases was introduced about 70 years ago, however, there is still a lack of consensus regarding indications, doses and procedure. This review covers treatment results in immunogenic hyperthyroidism including the problem of orbitopathy. Radioiodine therapy for toxic and non-toxic multinodular goiter is also discussed with striking possibility of enhanching the radioiodine uptake. In this respect the recombinant human thyrotropin should be mentioned. Thyroid cancer treatment protocol has changed, too, due to ineffectivity in low-risk patients. More attention is needed to the carcinogenecity of radioiodine. The numerous problems mentioned above require large and well-designed prospective trials to resolve the fundamental questions. The author emphasizes that radioiodine dose should be administered in doses as low as reasonably achievable. Orv. Hetil., 2016, 157(3), 83–88.

scholarly journals Single, very low dose (0.03 mg) of recombinant human thyrotropin (rhTSH) effectively increases radioiodine uptake in the I-131 treatment of large nontoxic multinodular goiter

2016 ◽  
Vol 19 (1) ◽  
pp. 3-11 ◽  
Author(s):  
Małgorzata Natalia Mojsak ◽  
Saeid Abdelrazek ◽  
Piotr Szumowski ◽  
Franciszek Rogowski ◽  
Monika Sykała ◽  
...  
Keyword(s):  
Multinodular Goiter ◽  
Low Dose ◽  
Radioiodine Uptake ◽  
Recombinant Human Thyrotropin

scholarly journals Treatment of thyrotoxicosis with radioiodine (аnalytical review of literature and own clinical data)

2020 ◽  
Vol 28 (3) ◽  
pp. 241-254
Author(s):  
N. I. Lukhovytska
Keyword(s):  
Thyroid Gland ◽  
Multinodular Goiter ◽  
Radioiodine Therapy ◽  
Severe Disease ◽  
Graves Disease ◽  
Radioiodine Treatment ◽  
Sources Of Information ◽  
Toxic Multinodular Goiter ◽  
Medical Radiology ◽  
Almost All

Background. Thyrotoxicosis syndrome is a severe disease of the thyroid that adversely affects functioning of almost all organs and body systems and can result in serious complications like ciliary arrhythmia, cardiovascular inefficiency, thyroid eye disease with visual deterioration, multi-organ failure. The choice of treatment strategy, its sequence and radioiodine therapy effectiveness in thyrotoxicosis and other non-oncological diseases of the thyroid gland is still a challenging issue in endocrinology and radiology. Purpose. To analyze the literature data regarding radionuclide treatment in patients with thyrotoxicosis and to present own experience-outcomes of radioiodine treatment administered to 146 patients with thyrotoxicosis symptoms and 9 patients with other non-oncological thyroid pathology at SO «Grigoriev Institute for Medical Radiology and Oncology» during 2010–2019. Materials and methods. The literature analysis involved 34 sources of information in the form of scientific articles, research papers, monographies, etc. Among them, 4 sources were domestic, 3 sources were Russian, the other 27 were taken from the foreign scientific journals. The evidence level of researching varies from І А to ІІІ С. The analysis of own findings has been carried out for the period from 2010 to the first half of 2020. Treatment with 131I-sodium iodide was provided in liquid or capsule form, per os; 155 patients in total underewnt treatment. Radioiodine activity per a course ranged from 185 MBq to 1110 MBq, the number of courses was chosen individually. Results and discussion. The analytical review of modern domestic and foreign literature has made it possible to define that radioiodine treatment still plays an important role in treatment of thyrotoxicosis, especially for patients with recurrent and resistant to thyrostatics disease form. Our own data showed that the treatment was reasonable to be administered via high radioiodine doses (600–1000 MBq), that resulted in curing the disease in 98 % (113 patients with Graves’ disease and 33 patients with toxic multinodular goiter). The effectiveness of radioiodine therapy for patients with AIT (2 cases) and in case of the retrosternal location of the thyroid gland (7 patients) has been proven. Conclusions. Radioiodine treatment remains a modern and effective way to overcome such conditions as Graves’ disease, TMNG (toxic multinodular goiter), retrosternal location of hyperplastic thyroid gland, AIT.

scholarly journals Thyroglobulin as a possible predictor of doses radioiodine therapy in hyperthyroidism

2018 ◽  
Vol 48 (1-2) ◽  
Author(s):  
Salih Azabagić
Keyword(s):  
Multinodular Goiter ◽  
Radioiodine Therapy ◽  
Cost Effective ◽  
Antithyroid Drugs ◽  
Toxic Adenoma ◽  
Effective Treatment Option ◽  
Average Value ◽  
Cost Effective Treatment ◽  
Toxic Multinodular Goiter

Introduction According to guidelines for the management of hyperthyroidism, patients with hyperthyroidism should be treated with radioactive iodine, antithyroid drugs, or thyroidectomy. Oral administration of radioiodine is a safe and cost effective treatment option for patients with toxic multinodular goiter (TMG)/toxic adenoma (TA) or Grave’s disease (GD). The aim of the study was to evaluate the use of thyroglobulin values as a possible predictor of a dose of radioiodine therapy (RAI) in hyperthyroidism in patients GD, TA and TMG. Results The study included 105 patients (14.4 % males and 85.6% females). The average duration of the disease was 9 years. Graves’s disease is registered among 50.68%, toxic multinodular goiter among 30.83% and toxic adenoma among 18.49% of patients. Patients were divided into four groups, and they received four doses of radioiodine therapy: 10mCi, 15mCi, 20mCi and 25mCi. The values of thyroglubulin were measured before RAI, and in period of one, three and six months after the therapy. Conclusion It can be concluded that the higher average value of thyroglobulin before therapy suggests the need for administering a higher doses of RAI, so determination of thyroglobulin levels in serum, may serve as a good predictor to assist in monitoring the administered dose of RAI in patients with hyperthyroidism.

Frequency of Pathological Types of Hyperthyroidism in Thyroid Scan Patients

2020 ◽  
Vol 16 ◽  
Author(s):  
Ali Pooria ◽  
Afsoun Pourya ◽  
Alireza Gheini
Keyword(s):  
Multinodular Goiter ◽  
Clinical Information ◽  
Thyroid Stimulating Hormone ◽  
Graves Disease ◽  
Toxic Adenoma ◽  
Aged Patients ◽  
Cross Sectional ◽  
Radioiodine Uptake ◽  
Systemic Disorder ◽  
Toxic Multinodular Goiter

Background: Hyperthyroidism is a common systemic disorder where Graves’ disease is known as the leading cause of the disease. Thyroid stimulating hormone, T4 and T3 antibody assay are usually performed for the diagnosis of the pathology. However, with uncertainty in the results and in order to estimate the magnitude and the exact cause of the disease, radioactive iodine uptake (RAIU) test is recommended. The aim of this study is to evaluate underlying pathology in the patients presenting hyperthyroidism using RAIU test results. Methods: This is a cross-sectional retrospective study conducted on the patients with hyperthyroidism referred to Shahid Madani Hospital in Khorramabad. Data regarding the biochemical analysis and RAIU test was collected from the records and a questionnaire based on demographic and clinical information was completed for each patient. Results: Of 137 patients presenting hyperthyroidism, 62.04% were presented with Graves’ disease, 24.08% with toxic multinodular goiter and 13.86% with toxic adenoma. 24-hour RAIU test showed that the percent of radioiodine uptake was most in toxic adenoma 67.7%, Graves’ disease 53.5% and multinodular goiter 39%, respectively. From the age-based analysis, we found that Graves’ was most common in 20-30 years old individuals 34%, multinodular goiter in 50+ aged individuals 36.3% and toxic adenoma was most prevalent in 30-40 and 50+ aged patients, 26.3% each. In our population of interest, 81.8% toxic multinodular goiter patients were females. Conclusions: Our study presents the outcome of RAIU tests in hyperthyroidism based on the underlying pathologies. We also conclude, in light of other findings, Graves’ disease is the most common cause of hyperthyroidism in our population.

Sign in / Sign up

Export Citation Format

Share Document